Praxis Precision Medicines (PRAX) Equity Average: 2022-2025
Historic Equity Average for Praxis Precision Medicines (PRAX) over the last 4 years, with Sep 2025 value amounting to $373.9 million.
- Praxis Precision Medicines' Equity Average fell 6.74% to $373.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $373.9 million, marking a year-over-year decrease of 6.74%. This contributed to the annual value of $257.6 million for FY2024, which is 253.37% up from last year.
- Praxis Precision Medicines' Equity Average amounted to $373.9 million in Q3 2025, which was down 11.35% from $421.7 million recorded in Q2 2025.
- Over the past 5 years, Praxis Precision Medicines' Equity Average peaked at $442.3 million during Q1 2025, and registered a low of $70.3 million during Q1 2023.
- Moreover, its 3-year median value for Equity Average was $324.4 million (2024), whereas its average is $259.7 million.
- Its Equity Average has fluctuated over the past 5 years, first slumped by 48.44% in 2023, then soared by 429.40% in 2024.
- Quarterly analysis of 4 years shows Praxis Precision Medicines' Equity Average stood at $90.6 million in 2022, then decreased by 13.71% to $78.2 million in 2023, then spiked by 429.40% to $414.1 million in 2024, then declined by 6.74% to $373.9 million in 2025.
- Its Equity Average stands at $373.9 million for Q3 2025, versus $421.7 million for Q2 2025 and $442.3 million for Q1 2025.